Journal ArticleDOI
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer
Arlene A. Forastiere,Helmuth Goepfert,Moshe H. Maor,Thomas F. Pajak,Randal S. Weber,William H. Morrison,Bonnie S. Glisson,Andy Trotti,John A. Ridge,C. Chao,Glen Peters,Ding Jen Lee,Andrea Leaf,John F. Ensley,Jay S. Cooper +14 more
TLDR
In patients with laryngeal cancer, radiotherapy with concurrent administration of cisplatin is superior to induction chemotherapy followed by radiotherapy or radiotherapy alone for larynGEal preservation and locoregional control.Abstract:
Background Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. Methods We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. Results A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 ...read more
Citations
More filters
Journal ArticleDOI
Total laryngectomy or laryngeal preservation for advanced laryngeal cancer. Impact of the functional risk upon the patient's preferences.
TL;DR: Laryngeal preservation is not a major objective of treatment shared by patients filling a questionnaire devoted to the choice of treatment when facing an advanced laryngeAL cancer.
Journal ArticleDOI
Concurrent chemoradiotherapy with cisplatin or cetuximab for locally advanced head and neck squamous cell carcinomas: Does human papilloma virus play a role?
Dan Ou,Dan Ou,Antonin Levy,Pierre Blanchard,Ingrid Garberis,Odile Casiraghi,Jean-Yves Scoazec,François Janot,Stéphane Temam,Eric Deutsch,Yungan Tao +10 more
TL;DR: Long-term results suggested better outcomes in LAHNSCC patients receiving concurrent cisplatin over cetuximab regardless of HPV/p16 status, especially in human papilloma virus-associated patients.
Journal ArticleDOI
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
TL;DR: It is demonstrated that long term administration of Bevacizumab effectively modulates chemotherapeutic efficacy against HNSCC xenografts and further investigation into the therapeutic potential of this combination strategy against H NSCC is warranted.
Journal ArticleDOI
Induction chemotherapy in head and neck cancer: a new paradigm.
TL;DR: This review summarizes the rationale, data, and perspectives on induction chemotherapy-based strategies, and the decision to deliver induction chemotherapy (and its intensification) must be considered in the light of other treatments aiming at better locoregional control.
Journal ArticleDOI
Outcomes of Induction Chemotherapy for Head and Neck Cancer Patients: A Combined Study of Two National Cohorts in Taiwan.
Jin-Hua Chen,Yu-Chun Yen,Shing-Hwa Liu,Sheng Po Yuan,Li Li Wu,Fei Peng Lee,Kuan Chou Lin,Ming-Tang Lai,Chia Che Wu,Tsung Ming Chen,Chia Lun Chang,Jyh-Ming Chow,Yi Fang Ding,Ming Chin Lin,Szu-Yuan Wu +14 more
TL;DR: Compared with CCRT alone, docetaxal- or platinum-based induction CT did not improve survival but increased the risk of all-cause and head and neck cancer-related death.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal Article
Evaluation of survival data and two new rank order statistics arising in its consideration.
Journal ArticleDOI
A Multiple Comparison Procedure for Comparing Several Treatments with a Control
TL;DR: In this article, a multiple comparison procedure for comparing several treatments with a control is presented, which is based on the Multiple Comparison Procedure for Comparing Several Treatments with a Control (MCPC).
Journal ArticleDOI
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
TL;DR: In this paper, a class of tests developed for comparing the cumulative incidence of a particular type of failure among different groups is presented. The tests are based on comparing weighted averages of the hazards of the subdistribution for the failure type of interest.
Journal ArticleDOI
Cancer statistics, 2003.
TL;DR: The American Cancer Society estimates the number of new cancer cases and deaths expected in the United States in the current year, and compiles the most recent data on cancer incidence, mortality, and survival by using incidence data from the National Cancer Institute (NCI) and mortality data from National Center for Health Statistics (NCHS).